RLAY
Relay Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.04
+0.16%Year over year
Reported trailing growth
- Revenue
- +23.9%
- EBITDA
- +11.4%
- EBIT
- +9.5%
- EPS
- +19.5%
- Free cash flow
- +19.0%
- Operating cash flow
- +18.8%
Forward estimates
Based on analyst estimates
- Revenue
- -0.8%
- EBITDA
- -10.4%
- EPS
- -0.6%
Three-year CAGR
- Revenue
- +123.2%
- EBITDA
- +28.2%
- EBIT
- +18.7%
- Net income
- +18.1%
- EPS
- +31.8%
- Free cash flow
- +6.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026